Cover Image
市場調查報告書

膽囊癌:開發中產品分析

Gallbladder Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360915
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
膽囊癌:開發中產品分析 Gallbladder Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 118 Pages
簡介

本報告提供膽囊癌治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

膽囊癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

膽囊癌:企業開發中的治療藥

膽囊癌:大學/機關研究中的治療藥

膽囊癌:開發中產品概況

  • 臨床階段的產品

膽囊癌:企業開發中的產品

膽囊癌:大學/機關研究中的產品

膽囊癌治療藥的開發企業

  • 4SC AG
  • Array BioPharma Inc.
  • Novartis AG
  • Spectrum Pharmaceuticals, Inc.
  • VasGene Therapeutics, Inc.

膽囊癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

膽囊癌:最近的開發平台趨勢

膽囊癌:暫停中的計劃

膽囊癌:開發中止的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9392IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gallbladder Cancer - Overview
    • Gallbladder Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Gallbladder Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gallbladder Cancer - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • Array BioPharma Inc
    • Aslan Pharmaceuticals Pte Ltd
    • Bayer AG
    • BeiGene Ltd
    • Eli Lilly and Company
    • Halozyme Therapeutics Inc
    • Hutchison China MediTech Ltd
    • Leap Therapeutics Inc
    • Merrimack Pharmaceuticals Inc
    • Novartis AG
    • NuCana BioMed Ltd
    • Threshold Pharmaceuticals Inc
    • VasGene Therapeutics Inc
  • Gallbladder Cancer - Drug Profiles
    • apatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGBA-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DKN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evofosfamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NUC-1031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEGPH-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramucirumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • varlitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vas-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gallbladder Cancer - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Gallbladder Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Gallbladder Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
  • Gallbladder Cancer - Pipeline by Bayer AG, H1 2017
  • Gallbladder Cancer - Pipeline by BeiGene Ltd, H1 2017
  • Gallbladder Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
  • Gallbladder Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
  • Gallbladder Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Gallbladder Cancer - Pipeline by Novartis AG, H1 2017
  • Gallbladder Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
  • Gallbladder Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
  • Gallbladder Cancer - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Gallbladder Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top